News >

Chemotherapy Triplet Elicits Encouraging Activity in Pancreatic Adenocarcinoma

Caroline Seymour
Published: Thursday, Oct 17, 2019

Daniel D. Von Hoff, MD, FACP

Daniel D. Von Hoff, MD, FACP

The addition of cisplatin to gemcitabine and nab-paclitaxel (Abraxane) resulted in encouraging activity in patients with previously untreated advanced pancreatic cancer, despite not having demonstrated the prespecified number of complete responses (CRs) to meet the primary endpoint of a phase Ib/II clinical trial (NCT01893801), according to findings published in JAMA Oncology.1,2

As such, the regimen is also being explored in the neoadjuvant pancreatic cancer setting (NCT03138720) as well as in patients with advanced biliary cancers (NCT02392637).

References

  1. TGen-HonorHealth Clinical trial shows tumor shrinkage in 71 percent of patients with late-stage pancreatic cancer. TGen. Published October 3, 2019. Accessed October 17, 2019. https://bit.ly/33gsQ4l.
  2. Jameson G, Borazanci E, Babiker H, et al. Response rate following albumin-bound paclitaxel plus gemcitabine plus cisplatin treatment among patients with advanced pancreatic cancer [published online October 3, 2019]. JAMA Oncol. doi: 10.1001/jamaoncol.2019.3394.

... to read the full story
To Read the Full Story

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Publication Bottom Border
Border Publication
x